Source link : https://europ.info/2026/09/27/sandoz-expands-biosimilar-manufacturing-with-new-drug-substance-facility-in-ljubljana-slovenia/
Sandoz, a global leader in biosimilars and generic medicines, has announced a significant investment in a new drug substance facility located in Ljubljana, Slovenia. This strategic move aims to expand the company’s biosimilar manufacturing capacity, reinforcing its commitment to increasing access to affordable, high-quality medicines worldwide. The state-of-the-art facility is expected to enhance production capabilities and support Sandoz’s growing portfolio of biosimilar therapies, marking a pivotal step in the company’s ongoing efforts to meet rising global demand.
Sandoz Strengthens Biosimilar Production with New Ljubljana Facility
Sandoz has officially expanded its global footprint with the launch of a cutting-edge drug substance manufacturing facility in Ljubljana, Slovenia. This strategic investment is positioned to significantly increase the company’s capacity to produce high-quality biosimilars, reinforcing its commitment to making advanced therapies more accessible worldwide. Equipped with state-of-the-art technology and designed with sustainability in mind, the new site underscores Sandoz’s dedication to innovation and operational excellence within the competitive biosimilar market.
The Ljubljana facility is expected to accelerate product development timelines and improve overall supply chain resilience. Key features of the new site include:
- Advanced bioreactor systems enabling scalable production
- Enhanced quality control laboratories adhering to…
—-
Author : Ava Thompson
Publish date : 2026-09-27 12:35:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8